Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Duke University Identifier:
First received: August 10, 2006
Last updated: July 9, 2014
Last verified: February 2013

August 10, 2006
July 9, 2014
April 2004
August 2007   (final data collection date for primary outcome measure)
6-month overall survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00362921 on Archive Site
  • One year overall survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • 2 year overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Median overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Toxicity prevalence [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Gliadel Plus 06-Benzylguanine for Patients With Recurrent Glioblastoma Multiforme

RATIONALE: Drugs used in chemotherapy, such as Gliadel wafer and O6-benzylguanine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving Gliadel wafer together with O6-benzylguanine works in treating patients with recurrent glioblastoma multiforme.


  • Define the activity of Gliadel® wafers in combination with a 5-day infusion of O6-benzylguanine in patients with recurrent glioblastoma multiforme.
  • Define the toxicity of Gliadel® wafers in combination with 5-day infusion of O6-benzylguanine in patients with recurrent glioblastoma multiforme.

OUTLINE: This is an open-label study.

Patients undergo surgical resection of tumor followed by placement of Gliadel® wafers . Within 6 hours after completion of surgery, patients receive a 1 hour high dose infusion of O6-benzylguanine followed by a lower dose continuous infusion for 5 days. Every 48 hours a repeat infusion of the high dose over 1 hour will be administered for a total of 3 doses.

After completion of study treatment, patients are followed every 8 weeks.

PROJECTED ACCRUAL: A total of 50 patients should be accrued for this study.

Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Recurrent Adult Brain Tumor
Drug: Gliadel wafers in combination with O6-benzylguanine
Other Name: Gliadel wafer (carmustine)
Experimental: Gliadel wafers in combination with O6-benzylguanine
Intervention: Drug: Gliadel wafers in combination with O6-benzylguanine
Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 2009 Feb 1;15(3):1064-8. doi: 10.1158/1078-0432.CCR-08-2130.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2008
August 2007   (final data collection date for primary outcome measure)



  • Histologically confirmed recurrent glioblastoma multiforme (including gliosarcoma) which can be confirmed, if not earlier, by intraoperative pathological diagnosis on frozen section
  • Evidence of a unilateral, single focus of measurable Central Nervous System (CNS) neoplasm on contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) scan that is supratentorial and measures ≥ 1.0 cm in diameter


  • Greater than or equal to 18 years old
  • Life expectancy of greater than 12 weeks
  • Karnofsky performance status greater than or equal to 60%
  • Absolute neutrophil count ≥ 1,000/millimeters (mm)³
  • Platelet count ≥ 100,000/mm³
  • Total Serum Bilirubin < 2 times upper limit of normal (ULN)
  • Serum glutamic oxaloacetic transaminase (SGOT) < 3 times ULN
  • Blood urea nitrogen (BUN) < 1.5 times ULN
  • Creatinine < 1.5 times ULN
  • Negative pregnancy test
  • Recovered from any effects of major surgery
  • Patients or legal guardian must give written, informed consent.


  • At least 2 weeks since prior surgical resection (if conducted) and recovered, unless there is unequivocal evidence of tumor progression
  • At least 4 weeks since prior radiotherapy or chemotherapy (6 weeks for nitrosoureas), unless there is unequivocal evidence of tumor progression.. However, patients treated with chemotherapeutic agents such as etoposide who would normally be retreated after shorter intervals (eg, 21 days on, 7 days off schedule) may be treated at the usual starting time even if less than 4 weeks from the last prior dose of chemotherapy.


  • Patients who have not recovered from surgery
  • Patients who are not neurologically stable for 2 weeks prior to study entry
  • Patients who are poor medical risks because of non-malignant systemic disease as well as those with acute infection treated with intravenous antibiotics
  • Frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction)
  • Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
  • Known HIV positivity or AIDS-related illness
  • Pregnant or nursing women
  • Women of childbearing potential who are not using an effective method of contraception. Women of childbearing potential must have a negative serum pregnancy test 24 hours prior to administration of study drug and be practicing medically approved contraceptive precautions.
  • Men who are not advised to use an effective method of contraception
  • Patients taking immuno-suppressive agents other than prescribed corticosteroids
  • Patients who have had prior treatment with Gliadel Wafers.
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Pro00004127, DUMC-5515-06-1R2, DUMC-5515-04-1R0, GP-DUMC-5515-06-1R2, CDR0000483768
Not Provided
Not Provided
Duke University
Duke University
National Cancer Institute (NCI)
Study Chair: Jennifer A. Quinn, MD Duke Cancer Institute
Duke University
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP